DARA Biosciences (DARA)
DARA Biosciences Liabilities: 1.759M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
DARA Liabilities Rankings
| Overall | 98th percentile | 59 of 4384 |
| Sector | 97th percentile | 15 of 504 in Healthcare |
| Industry | 96th percentile | 5 of 159 in Biotechnology |
DARA Liabilities Range, Past 5 Years
| Minimum | 0.7004M | Sep 2011 |
| Maximum | 2.948M | Mar 2008 |
| Average | 1.702M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these DARA related companies
DARA News
DARA BioSciences (DARA) to Continue KRN5500 Development Following Phase 2a Data
May 09, 8:46AM Street Insider
May 09, 8:46AM Street Insider
$DARA securities sale nets $9.2M; proceeds to support cancer portfolio. http://stks.co/3OZY
about 40 days ago by abubnic
about 40 days ago by abubnic
$DARA on radar this morning. They raised $10 mil in $1.00 stock sale. I anticipate continue rise in value. I am Long.
about 48 days ago by Flynt2012
about 48 days ago by Flynt2012
$DARA filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3EfK
about 53 days ago by MarketBrief
about 53 days ago by MarketBrief
$ZLCS - cashed out. Entered $DARA because of the accumulation on the daily chart. Look at the high volume days
about 61 days ago by britepathos
about 61 days ago by britepathos
DARA BioSciences (DARA) Enters Exclusive Bionect Distribution Agreement with Innocutis
Mar 26, 8:49AM Street Insider
Mar 26, 8:49AM Street Insider
$DARA ]Obtains U.S. Rights to Co-Promote Bionect an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets
about 63 days ago by Benzinga
about 63 days ago by Benzinga
Biotech: DARA Focuses On Oncology: The Right Move $DARA $QQQ $$ #Biotech #KSMT http://stks.co/2gU6 via @jnapodano
about 84 days ago by MichaelKudrna
about 84 days ago by MichaelKudrna
Dara (DARA) Pens Exclusive Agreement with Uman for US Commercialization Rights to Gemcitabine
Feb 15, 8:33AM Street Insider
Feb 15, 8:33AM Street Insider
$DARA nice micro bio run today. $ABIO still my favorite that has not run yet. Holding some.
about 111 days ago by GarethSoloway
about 111 days ago by GarethSoloway
DARA BioSciences (DARA) Enters $1.7M Financing Though Series B Convertible Preferred Sale
Jan 18, 8:46AM Street Insider
Jan 18, 8:46AM Street Insider
DARA BioSciences Signs Definitive Agreement to Raise $1.7 Million in Registered Direct Offering
Jan 18, 8:45AM Benzinga
Jan 18, 8:45AM Benzinga
Seems like a nice little coup for $LTS that they were the advisor on the $DARA - Oncogenerix deal.
about 132 days ago by bradloncar
about 132 days ago by bradloncar
$DARA acquisition will provide opportunity in multiple segments lucrative cancer market, currently valued in excess of $48 billion $PFE $MRK
about 132 days ago by TwitStocks
about 132 days ago by TwitStocks
$DARA enters niche market as the only FDA approved
liquid formulation of tamoxifen available for sale in the United States $BMY $MRK $PFE
about 132 days ago by TwitStocks
about 132 days ago by TwitStocks
DARA BioSciences (DARA) Makes David Drutz Permanent CEO; Steve Gorlin Appointed to Board
Dec 20, 8:46AM Street Insider
Dec 20, 8:46AM Street Insider
$DARA small bio on my radar. Someone slowly accumulating down here as it floats up. Hmmmm.
about 171 days ago by GarethSoloway
about 171 days ago by GarethSoloway
Emerging Biotech Companies Discuss What’s in the Pipeline at NYSSA Conference
Nov 10, 10:00AM Business Wire
Nov 10, 10:00AM Business Wire
Five New U.S. and Foreign Patents Have Been Granted to DARA BioSciences, Inc.
Nov 08, 8:00AM GlobeNewswire
Nov 08, 8:00AM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| DARA | 0.8476 | -0.00 | -0.28% | 6.34M |
| DAR | 14.26 | -0.04 | -0.28% | 1.673B |
| DANG | 5.38 | -0.17 | -3.06% | 427.17M |
| DAN | 13.39 | -0.17 | -1.25% | 1.975B |
| DAL | 11.37 | +0.10 | +0.89% | 9.614B |
| DAKT | 7.15 | -0.03 | -0.42% | 299.23M |
| CY | 13.25 | +0.11 | +0.84% | 2.052B |
| CXZ | 0.35 | -0.01 | -2.78% | 18.86M |
| CXW | 26.08 | -0.18 | -0.69% | 2.596B |
| CXS | 10.02 | -0.06 | -0.60% | 767.73M |
